The Secondary Efficacy Evaluations Include: MADRS, PANSS Total Scores and Subscales and Responder Rate; CGI-S and CGI-I Scales.
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Efficacy and Safety of Ziprasidone to Treat Depressive Symptoms in Patients With Schizophrenia (NCT01260116) | Wuhan University | 2010-12-01 |
Track The Secondary Efficacy Evaluations Include: MADRS, PANSS Total Scores and Subscales and Responder Rate; CGI-S and CGI-I Scales. automatically
Every clearance here is in the API, with alerts when new ones post.